What's new

Post-hoc Analysis of HARBOR Trial Provides New Insights Into the Relationship Between Atrophy and Anti-VEGF Therapy
Nov 18, 2014    Clinical Updates
Iluvien Receives Marketing Authorization in Ireland for Chronic DME
Nov 17, 2014    Industry News
Actavis to Acquire Allergan
Nov 17, 2014    Industry News
FDA Announces Eylea Safety Labeling Changes
Nov 17, 2014    Clinical Updates
November Featured Surgical Video: Transscleral Biopsy of a Choroidal Mass
Nov 12, 2014    Clinical Updates
Aetna National Medical Director Supports Physician Choice and Agrees to Fix Drug Underpayments
Nov 10, 2014    Advocacy & Practice Updates
Detailed Summary of 2015 PQRS Changes Now Available
Nov 5, 2014    Advocacy & Practice Updates
Heavy Payment Cuts to Retina Procedures in 2015 Under CMS’s Misvalued Codes Initiative
Oct 31, 2014    Advocacy & Practice Updates

Retina Times

Fall 2014, Vol. 32, No. 4, Iss. 56

In this issue:

ASRS 32nd Annual Meeting Highlights
ASRS 32nd Annual Meeting Draws 1798—a 15% Increase Over Last Year’s Record Attendance

International Corner/Retinomics
First Global Trends in Retina Survey Explores Practice Patterns -- PART 1: MEDICAL RETINA HIGHLIGHTS

 Retinomics Perspectives
‘Narrow Network’ Plans on the ACA’s Insurance Exchange May Restrict Access to Retina Specialists

Research & Development
PART 3 IN A SERIES: Considering the Long-Term Effects of Anti-VEGF Treatment

Part 2 of 2: How Will Health System Changes Affect Your Practice?

Block Time
SCORE2 Compares Avastin, Eylea for CRVO

Read all articles »


17th Annual Practice Management Issues Seminar
March 28-29, 2015
Dallas, Texas

ASRS 33rd Annual Meeting
July 11-14, 2015
Vienna, Austria